To this end, the performance of soluble CD163 (sCD163) and different cytokines has been assessed in several clinical studies of cirrhotic patients with chronic liver diseases and/or HCC, providing efficient non-invasive markers for HCC risk and/or progression [42–45]. This evidence concerns the gene CD163 and hepatocellular carcinoma.